Predicting early transition from sub-syndromal presentations to major mental disorders.
Predicting early transition from sub-syndromal presentations to major mental disorders.
复制标题
DOI：
10.1192/bjpo.bp.117.004721
复制
发表时间：
2017-09
期刊：
影响因子：
5.4
通讯作者：
Hickie IB
中科院分区：
文献类型：
--
作者：
Cross SPM;Scott J;Hickie IB
与精神病相比，从高危状态到完全综合征性精神障碍的转变在单相和双相情感障碍中的研究还不够深入。从亚阈值到完全综合征性精神障碍早期转变的比率和预测因素的前瞻性跨诊断研究。243例年龄在15-25岁之间、有潜在严重精神障碍亚综合征表现的青年患者的1年结局。从基线临床和人口统计学评级中确定的过渡预测因素的生存分析和比值比（OR）。约17%（n=36）的患者经历了向严重精神障碍的转变。独立的综合征诊断，过渡是显着更有可能在个人谁是NEET（没有在教育，就业或培训），在女性和那些更消极的心理症状（如社会退缩）。NEET状态和阴性症状是诊断类别中疾病轨迹的可修改预测因子，并不特定于向精神病的转变。I.B.H.自2012年以来，他一直担任澳大利亚国家精神卫生委员会的委员。他是一个董事会成员顶空：国家青年心理健康基金会，直到2012年1月。他领导了一系列以社区为基础的和制药业支持的抑郁症意识和教育和培训计划。他领导了由政府，社区机构和制药行业合作伙伴（惠氏，礼来，施维雅，辉瑞，阿斯利康）支持的卫生专业人员和社区项目，用于识别和管理抑郁和焦虑。他曾在一些非政府组织和制药行业（包括施维雅，辉瑞，阿斯利康和礼来）支持的教育研讨会上介绍自己的工作。他是Medibank Private医疗咨询小组的成员，也是澳大利亚精神病信托基金的董事会成员。他领导了一项关于阿戈美拉汀对昼夜节律参数影响的研究（部分由施维雅支持），并参与了一项关于阿戈美拉汀对抑郁症睡眠结构影响的多中心临床试验，以及一项由施维雅支持的关于初级保健环境中重度抑郁症和睡眠障碍的研究。© 2017年皇家精神病学院。这是一篇开放获取的文章，根据知识共享非商业性，无衍生品（CC BY-NC-ND）许可证的条款分发。
Transition from at-risk state to full syndromal mental disorders is underexplored for unipolar and bipolar disorders compared with psychosis. Prospective, trans-diagnostic study of rates and predictors of early transition from sub-threshold to full syndromal mental disorder. One-year outcome of 243 consenting youth aged 15–25 years with a sub-syndromal presentation of a potentially severe mental disorder. Survival analysis and odds ratio (OR) for predictors of transition identified from baseline clinical and demographic ratings. About 17% (n=36) experienced transition to a major mental disorder. Independent of syndromal diagnosis, transition was significantly more likely in individuals who were NEET (not in education, employment or training), in females and in those with more negative psychological symptoms (e.g. social withdrawal). NEET status and negative symptoms are modifiable predictors of illness trajectory across diagnostic categories and are not specific to transition to psychosis. I.B.H. has been a Commissioner in Australia’s National Mental Health Commission since 2012. He was a board member of headspace: National Youth Mental Health Foundation until January 2012. He has led a range of community-based and pharmaceutical industry-supported depression awareness and education and training programmes. He has led projects for health professionals and the community supported by governmental, community agency and pharmaceutical industry partners (Wyeth, Eli Lilly, Servier, Pfizer, AstraZeneca) for the identification and management of depression and anxiety. He has received honoraria for presentations of his own work at educational seminars supported by a number of non-government organisations and the pharmaceutical industry (including Servier, Pfizer, AstraZeneca and Eli Lilly). He is a member of the Medical Advisory Panel for Medibank Private and also a board member of Psychosis Australia Trust. He leads an investigator-initiated study of the effects of agomelatine on circadian parameters (supported in part by Servier) and has participated in a multicentre clinical trial of the effects of agomelatine on sleep architecture in depression and a Servier-supported study of major depression and sleep disturbance in primary care settings. © The Royal College of Psychiatrists 2017. This is an open access article distributed under the terms of the Creative Commons Non-Commercial, No Derivatives (CC BY-NC-ND) license.
登录
查看更多内容
影响因子：
7.6
作者：
Baggio, Stephanie;Iglesias, Katia;Gmel, Gerhard
通讯作者：
Gmel, Gerhard
影响因子：
3.6
作者：
Shafer, A
通讯作者：
Shafer, A
影响因子：
6.9
作者：
Valmaggia, L. R.;Stahl, D.;McGuire, P. K.
通讯作者：
McGuire, P. K.
影响因子：
4.5
作者：
Yung, AR;Phillips, LJ;McGorry, PD
通讯作者：
McGorry, PD
影响因子：
4.5
作者：
Dragt, Sara;Nieman, Dorien H.;Linszen, Don H.
通讯作者：
Linszen, Don H.